Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder

Manuel Gardea-Resendez; Monica J. Taylor-Desir; Francisco Romo-Nava; David Bond; Eric J. Vallender; Alfredo B. Cuellar-Barboza; Miguel L. Prieto; Nicolas Nunez; Marin Veldic; Aysegul Ozerdem; Balwinder Singh; Matej Markota; Colin L. Colby; Brandon J. Coombes; Joanna M. Biernacka; Susan L. McElroy; Mark A. Frye

doi:10.1097/JCP.0000000000001532

Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder

Manuel Gardea-Resendez, Monica J. Taylor-Desir, Francisco Romo-Nava, David Bond, Eric J. Vallender, Alfredo B. Cuellar-Barboza, Miguel L. Prieto, Nicolas Nunez, Marin Veldic, Aysegul Ozerdem, Balwinder Singh, Matej Markota, Colin L. Colby, Brandon J. Coombes, Joanna M. Biernacka, Susan L. McElroy, Mark A. Frye

Psychiatry & Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Purpose Recognizing the negative impact that antipsychotic-induced movement disorders have on the quality of life and treatment outcomes in bipolar disorder (BD), this study aimed to assess clinical correlates and antipsychotic use patterns of tardive dyskinesia (TD+) in BD. Materials and Methods Participants with and without TD were included. Clinical variables were compared using t-test and χ2 test. Antipsychotic use patterns in TD+, including number of trials, mean doses, and estimated cumulative exposure, were assessed in a case-only analysis. Results The prevalence rate of TD was 5.1%. In comparison to the TD- group (n = 1074), TD+ participants (n = 58) were older, more likely to be female and have type I bipolar illness. There were 60.3% of the TD+ group that continued using antipsychotics at study entry and had a mean cumulative exposure to antipsychotics of 18.2 ± 15.6 years. Average dose, in haloperidol equivalents, was 5.9 ± 3.5 mg and 77.7% of the trials were second-generation antipsychotics. Conclusions This study confirms previously identified TD risk factors, such as age, sex, and bipolar subtype in a large BD cohort. Limitations included a cross-sectional design and the lack of tardive illness severity assessment. As atypical antipsychotics continue to be primary mood stabilization treatment, attempting to harmonize large data sets to identify additional biomarkers of tardive risk will optimize individualized care for patients with BD.

Original language	English (US)
Pages (from-to)	159-162
Number of pages	4
Journal	Journal of Clinical Psychopharmacology
Volume	42
Issue number	2
DOIs	https://doi.org/10.1097/JCP.0000000000001532
State	Published - 2022

Bibliographical note

Funding Information:
This study was supported, in part, by the Marriott Family Foundation and the Mayo Clinic Center for Individualized Medicine; none had a role in the design, conduct, analysis, or submission of the study. M.G.R. reports receiving support from the Marriot Family Foundation during the conduct of the study. M.A.F. reports receiving grants from the Marriott Family Foundation during the conduct of the study; receiving grants from the National Institute of Alcohol Abuse and Alcoholism and National Institute of Mental Health, National Institutes of Health, Assurex Health, Myriad, and Pfizer; being a consultant to Janssen Global Services LLC; receiving travel and hotel honoraria from CME Outfitters to give a lecture for continuing medical education credit and receiving support for a presentation from Sunovion. F.R.-N reports support fromthe Brain&Behavior Research Foundation NARSADYoung Investigator Award and having patent 62 581 968 pending. S.L.M. reports receiving personal fees for advisory boards and/or consultation from Allergan, Avanir, Idorsia, Mitsubishi Tanabe Pharma America, Myriad, Novo Nordisk, Opiant, Shire, Sunovion, and Takeda (Shire); receiving grant support from Azevan, Brainsway, Marriott Foundation, Medibio, Neurocrine, Novo Nordisk, Otsuka, and Sunovian; and receiving payments from Johnson & Johnson for being an inventor on US Patent 6 323 236 B2. B.S. has received research time support from Medibio. No other disclosures are reported. These data have not been previously presented at a meeting.

Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.

Keywords

antipsychotics
bipolar disorder
tardive dyskinesia

PubMed: MeSH publication types

Journal Article

Access

10.1097/JCP.0000000000001532

OpenUrl availability

Full text

Cite this

Gardea-Resendez, M., Taylor-Desir, M. J., Romo-Nava, F., Bond, D., Vallender, E. J., Cuellar-Barboza, A. B., Prieto, M. L., Nunez, N., Veldic, M., Ozerdem, A., Singh, B., Markota, M., Colby, C. L., Coombes, B. J., Biernacka, J. M., McElroy, S. L., & Frye, M. A. (2022). Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder. Journal of Clinical Psychopharmacology, 42(2), 159-162. https://doi.org/10.1097/JCP.0000000000001532

Gardea-Resendez, M, Taylor-Desir, MJ, Romo-Nava, F, Bond, D, Vallender, EJ, Cuellar-Barboza, AB, Prieto, ML, Nunez, N, Veldic, M, Ozerdem, A, Singh, B, Markota, M, Colby, CL, Coombes, BJ, Biernacka, JM, McElroy, SL & Frye, MA 2022, 'Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder', Journal of Clinical Psychopharmacology, vol. 42, no. 2, pp. 159-162. https://doi.org/10.1097/JCP.0000000000001532

@article{3aa70abc087b4c93a819e3aae2ce22fe,

title = "Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder",

abstract = "Purpose Recognizing the negative impact that antipsychotic-induced movement disorders have on the quality of life and treatment outcomes in bipolar disorder (BD), this study aimed to assess clinical correlates and antipsychotic use patterns of tardive dyskinesia (TD+) in BD. Materials and Methods Participants with and without TD were included. Clinical variables were compared using t-test and χ2 test. Antipsychotic use patterns in TD+, including number of trials, mean doses, and estimated cumulative exposure, were assessed in a case-only analysis. Results The prevalence rate of TD was 5.1%. In comparison to the TD- group (n = 1074), TD+ participants (n = 58) were older, more likely to be female and have type I bipolar illness. There were 60.3% of the TD+ group that continued using antipsychotics at study entry and had a mean cumulative exposure to antipsychotics of 18.2 ± 15.6 years. Average dose, in haloperidol equivalents, was 5.9 ± 3.5 mg and 77.7% of the trials were second-generation antipsychotics. Conclusions This study confirms previously identified TD risk factors, such as age, sex, and bipolar subtype in a large BD cohort. Limitations included a cross-sectional design and the lack of tardive illness severity assessment. As atypical antipsychotics continue to be primary mood stabilization treatment, attempting to harmonize large data sets to identify additional biomarkers of tardive risk will optimize individualized care for patients with BD.",

keywords = "antipsychotics, bipolar disorder, tardive dyskinesia",

author = "Manuel Gardea-Resendez and Taylor-Desir, {Monica J.} and Francisco Romo-Nava and David Bond and Vallender, {Eric J.} and Cuellar-Barboza, {Alfredo B.} and Prieto, {Miguel L.} and Nicolas Nunez and Marin Veldic and Aysegul Ozerdem and Balwinder Singh and Matej Markota and Colby, {Colin L.} and Coombes, {Brandon J.} and Biernacka, {Joanna M.} and McElroy, {Susan L.} and Frye, {Mark A.}",

note = "Funding Information: This study was supported, in part, by the Marriott Family Foundation and the Mayo Clinic Center for Individualized Medicine; none had a role in the design, conduct, analysis, or submission of the study. M.G.R. reports receiving support from the Marriot Family Foundation during the conduct of the study. M.A.F. reports receiving grants from the Marriott Family Foundation during the conduct of the study; receiving grants from the National Institute of Alcohol Abuse and Alcoholism and National Institute of Mental Health, National Institutes of Health, Assurex Health, Myriad, and Pfizer; being a consultant to Janssen Global Services LLC; receiving travel and hotel honoraria from CME Outfitters to give a lecture for continuing medical education credit and receiving support for a presentation from Sunovion. F.R.-N reports support fromthe Brain&Behavior Research Foundation NARSADYoung Investigator Award and having patent 62 581 968 pending. S.L.M. reports receiving personal fees for advisory boards and/or consultation from Allergan, Avanir, Idorsia, Mitsubishi Tanabe Pharma America, Myriad, Novo Nordisk, Opiant, Shire, Sunovion, and Takeda (Shire); receiving grant support from Azevan, Brainsway, Marriott Foundation, Medibio, Neurocrine, Novo Nordisk, Otsuka, and Sunovian; and receiving payments from Johnson & Johnson for being an inventor on US Patent 6 323 236 B2. B.S. has received research time support from Medibio. No other disclosures are reported. These data have not been previously presented at a meeting. Publisher Copyright: {\textcopyright} Wolters Kluwer Health, Inc. All rights reserved.",

year = "2022",

doi = "10.1097/JCP.0000000000001532",

language = "English (US)",

volume = "42",

pages = "159--162",

journal = "Journal of Clinical Psychopharmacology",

issn = "0271-0749",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder

AU - Gardea-Resendez, Manuel

AU - Taylor-Desir, Monica J.

AU - Romo-Nava, Francisco

AU - Bond, David

AU - Vallender, Eric J.

AU - Cuellar-Barboza, Alfredo B.

AU - Prieto, Miguel L.

AU - Nunez, Nicolas

AU - Veldic, Marin

AU - Ozerdem, Aysegul

AU - Singh, Balwinder

AU - Markota, Matej

AU - Colby, Colin L.

AU - Coombes, Brandon J.

AU - Biernacka, Joanna M.

AU - McElroy, Susan L.

AU - Frye, Mark A.

N1 - Funding Information: This study was supported, in part, by the Marriott Family Foundation and the Mayo Clinic Center for Individualized Medicine; none had a role in the design, conduct, analysis, or submission of the study. M.G.R. reports receiving support from the Marriot Family Foundation during the conduct of the study. M.A.F. reports receiving grants from the Marriott Family Foundation during the conduct of the study; receiving grants from the National Institute of Alcohol Abuse and Alcoholism and National Institute of Mental Health, National Institutes of Health, Assurex Health, Myriad, and Pfizer; being a consultant to Janssen Global Services LLC; receiving travel and hotel honoraria from CME Outfitters to give a lecture for continuing medical education credit and receiving support for a presentation from Sunovion. F.R.-N reports support fromthe Brain&Behavior Research Foundation NARSADYoung Investigator Award and having patent 62 581 968 pending. S.L.M. reports receiving personal fees for advisory boards and/or consultation from Allergan, Avanir, Idorsia, Mitsubishi Tanabe Pharma America, Myriad, Novo Nordisk, Opiant, Shire, Sunovion, and Takeda (Shire); receiving grant support from Azevan, Brainsway, Marriott Foundation, Medibio, Neurocrine, Novo Nordisk, Otsuka, and Sunovian; and receiving payments from Johnson & Johnson for being an inventor on US Patent 6 323 236 B2. B.S. has received research time support from Medibio. No other disclosures are reported. These data have not been previously presented at a meeting. Publisher Copyright: © Wolters Kluwer Health, Inc. All rights reserved.

PY - 2022

Y1 - 2022

N2 - Purpose Recognizing the negative impact that antipsychotic-induced movement disorders have on the quality of life and treatment outcomes in bipolar disorder (BD), this study aimed to assess clinical correlates and antipsychotic use patterns of tardive dyskinesia (TD+) in BD. Materials and Methods Participants with and without TD were included. Clinical variables were compared using t-test and χ2 test. Antipsychotic use patterns in TD+, including number of trials, mean doses, and estimated cumulative exposure, were assessed in a case-only analysis. Results The prevalence rate of TD was 5.1%. In comparison to the TD- group (n = 1074), TD+ participants (n = 58) were older, more likely to be female and have type I bipolar illness. There were 60.3% of the TD+ group that continued using antipsychotics at study entry and had a mean cumulative exposure to antipsychotics of 18.2 ± 15.6 years. Average dose, in haloperidol equivalents, was 5.9 ± 3.5 mg and 77.7% of the trials were second-generation antipsychotics. Conclusions This study confirms previously identified TD risk factors, such as age, sex, and bipolar subtype in a large BD cohort. Limitations included a cross-sectional design and the lack of tardive illness severity assessment. As atypical antipsychotics continue to be primary mood stabilization treatment, attempting to harmonize large data sets to identify additional biomarkers of tardive risk will optimize individualized care for patients with BD.

AB - Purpose Recognizing the negative impact that antipsychotic-induced movement disorders have on the quality of life and treatment outcomes in bipolar disorder (BD), this study aimed to assess clinical correlates and antipsychotic use patterns of tardive dyskinesia (TD+) in BD. Materials and Methods Participants with and without TD were included. Clinical variables were compared using t-test and χ2 test. Antipsychotic use patterns in TD+, including number of trials, mean doses, and estimated cumulative exposure, were assessed in a case-only analysis. Results The prevalence rate of TD was 5.1%. In comparison to the TD- group (n = 1074), TD+ participants (n = 58) were older, more likely to be female and have type I bipolar illness. There were 60.3% of the TD+ group that continued using antipsychotics at study entry and had a mean cumulative exposure to antipsychotics of 18.2 ± 15.6 years. Average dose, in haloperidol equivalents, was 5.9 ± 3.5 mg and 77.7% of the trials were second-generation antipsychotics. Conclusions This study confirms previously identified TD risk factors, such as age, sex, and bipolar subtype in a large BD cohort. Limitations included a cross-sectional design and the lack of tardive illness severity assessment. As atypical antipsychotics continue to be primary mood stabilization treatment, attempting to harmonize large data sets to identify additional biomarkers of tardive risk will optimize individualized care for patients with BD.

KW - antipsychotics

KW - bipolar disorder

KW - tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=85125552800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125552800&partnerID=8YFLogxK

U2 - 10.1097/JCP.0000000000001532

DO - 10.1097/JCP.0000000000001532

M3 - Article

C2 - 35230047

AN - SCOPUS:85125552800

SN - 0271-0749

VL - 42

SP - 159

EP - 162

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

IS - 2

ER -

Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this